Primary Job Title President and Chief Executive Officer Primary Organization Pionyr Immunotherapeutics
Location San Francisco, California, United States Regions San Francisco Bay Area, West Coast, Western US Gender Male
LinkedIn View on LinkedIn
Steven James has 25 years of experience in the life sciences industry, including the creation and leadership of multiple companies. He is currently President and CEO of Pionyr Immunotherapeutics and was the President and CEO of Labrys Biologics from 2012 until it was acquired by Teva Pharmaceuticals in 2014. Prior to joining Labrys, Steven James
was President and CEO of KAI Pharmaceuticals from 2004 until the company was acquired by Amgen in 2012. His previous positions have included Senior Vice President of Commercial Operations at Exelixis, Chief Business Officer at Sunesis Pharmaceuticals and VP of Business Development at Isis Pharmaceuticals (now Ionis). He began his career in new product planning at Eli Lilly.
Steven James is Chairman of Antiva Biosciences, and a director of Chrono Therapeutics. He was formerly on the board of Cascadian Therapeutics (acquired by Seattle Genetics) and a past director of Ocera Therapeutics (acquired by Mallinckrodt). Steve holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree from Brown University.
